- Wednesday, April 21, 2021 @ 12:00 am
FY 2020 results were boosted by continued strong Cresemba sales and a one-time gain from the sale of the corporate HQ. The emerging cancer pipeline is rapidly progressing with 5 clinical trials ongoing for derazantinib and lisavanbulin with many data readouts ahead.
Key catalysts include:
Interim results “FIDES-02” trial derazantinib bladder cancer (H1 2021)
Topline results registrational trial Cresemba in Japan (H2 2021)
Complete enrollment phase III “ERADICATE” trial Zevtera bacteremia (H2 2021)
FY 2020 results were boosted by continued strong Cresemba sales and a one-time gain from the sale of the corporate HQ. The emerging cancer pipeline is rapidly progressing with 5 clinical trials ongoing for derazantinib and lisavanbulin with many data readouts ahead.
Key catalysts include
Interim results “FIDES-02” trial derazantinib bladder cancer (H1 2021)
Topline results registrational trial Cresemba in Japan (H2 2021)
Complete enrollment phase III “ERADICATE” trial Zevtera bacteremia (H2 2021)
